-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Elranatamab in Multiple Myeloma (Kahler Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Elranatamab in Multiple Myeloma (Kahler Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Elranatamab in Multiple Myeloma (Kahler Disease) Drug Details: Elranatamab-bcmm (Elrexfio)...
-
Company Insights
Innovation and Patenting activity of Y-mAbs Therapeutics Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Y-mAbs Therapeutics Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ctla 4 Mab in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ctla 4 Mab in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ctla 4 Mab in Solid Tumor Drug Details: The...
-
Product Insights
NewNet Present Value Model: Teva Pharmaceutical Industries Ltd’s Aflibercept Biosimilar
Empower your strategies with our Net Present Value Model: Teva Pharmaceutical Industries Ltd's Aflibercept Biosimilar report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Naxitamab in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Naxitamab in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Naxitamab in Triple-Negative Breast Cancer (TNBC) Drug Details: Naxitamab (Danyelza)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Naxitamab in Osteosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Naxitamab in Osteosarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Naxitamab in Osteosarcoma Drug Details: Naxitamab (Danyelza) is a monoclonal antibody, acts as...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OX-40 Agonist Mab in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OX-40 Agonist Mab in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OX-40 Agonist Mab in Solid Tumor Drug Details: Monoclonal...
-
Product Insights
NewNet Present Value Model: Inhibrx Inc’s INBRX-101
Empower your strategies with our Net Present Value Model: Inhibrx Inc's INBRX-101 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence. emphysema. The therapeutic candidate comprises of alpha-1 antitrypsin (AAT)-Fc fusion proteins and developed based...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GIM-122 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GIM-122 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GIM-122 in Solid Tumor Drug Details: GIM-122 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VB-119 in Focal Segmental Glomerulosclerosis (FSGS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VB-119 in Focal Segmental Glomerulosclerosis (FSGS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VB-119 in Focal Segmental Glomerulosclerosis (FSGS) Drug Details: VB-119 is...